Sabinsa’s C3 Reduct (registered trademark) is the only EFSA-approved reductive metabolites of curcuminoids on the market. Direct assimilation in the body as beneficial, bioavailable metabolites enables product formulators to appeal to consumers looking for proven, science-backed products. Indeed, consumers are increasingly looking for natural, functional preventive solutions that can better support their efforts to keep fit and healthy.
Curcumin, the principal curcuminoid sourced from the spice turmeric, has gained increasing global recognition for its multiple health benefits, in particular its antioxidant and anti-inflammatory properties. As a result, the ingredient is used as a means of supporting healthy living and longevity, and in managing inflammation and joint soreness.
A principal advantage of C3 Reduct is that these benefits are concentrated and enhanced. C3 Reduct, wherein curcuminoids are already converted to Tetrahydrocurcuminoids (THC’s), means that the product is directly assimilated in the body as beneficial metabolites. This is important, as the metabolites are more bioavailable than the parent curcuminoids.
In fact, C3 Reduct is the only EFSA-approved product of its kind on the market. Other curcumin-based products have to deliver curcumin in large doses to offer functionality. With C3 Reduct however, manufacturers can avoid the need to up dosages or mix curcumin with other artificial additives to increase bioavailability. This is because C3 Reduct delivers active metabolites directly to the body.
Curcumin is also yellow in colour, which can lead to staining issues along the production line. C3 Reduct can also help product developers to overcome this issue, because THCs are colourless. Manufacturers therefore do not have to worry about staining or off-colours.
The purpose of this White Paper is to help product developers better understand the functional benefits of C3 Reduct, to identify formulation opportunities and to bring to market health and wellness products that meet consumer demands.